Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II open-label study of MEK162 in BRAF V600- or NRAS-mutant advanced cutaneous melanoma
NL-OMON47322Phase 2Active, not recruiting
- Sponsor
- Pfizer
- Start
- Mar 2011
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of binimetinib in melanoma (2 cohorts), sponsored by Pfizer. Primary endpoint: Objective response rate. Started Mar 2011; status: active, not recruiting.
02
Drugs
binimetinib
03
Conditions
melanoma
Beyond the preview
Go deeper on NL-OMON47322.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON47322.